In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant ...

PURPOSEThe open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus durvalumab (Arm 7 ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

WILMINGTON, Del., September 15, 2024--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically ...

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in ...

Durvalumab is a selective, high-affinity, human IgG1 monoclonal antibody that inhibits interaction of PD-L1 with PD-1 and CD80 by binding to PD-L1. 28 Findings from the PACIFIC trial have ...

An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non ...

However, the best timing of starting durvalumab after completion of chemoradiation has not been identified. Progression-free survival (PFS) and overall survival (OS) were better in the subgroup of ...

As expected, grade 3/4 adverse events were slightly more common with durvalumab than with placebo, seen in 29.9% vs 26.1% of patients, with adverse events leading to discontinuation experienced by ...